Q1 2025 Management View Chirag Patel, Co-Founder and Co-CEO, highlighted Q1 2025 performance with revenues of $695 million ...

Viking Therapeutics (NASDAQ:VKTX) and other developers of oral weight loss drugs traded sharply higher on Tuesday after ...

If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York start-up Metsera. After emerging from stealth with a $290 ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid ...

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to ...

Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Metsera, Inc. (MTSR – Research Report) today and set a price target ...

Metsera , Inc. (NASDAQ:MTSR), a pharmaceutical company with a market capitalization of $1.95 billion, announced today the appointment of Jon P. Stonehouse to its Board of Directors and Matthew ...

In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other top insider purchases last month. Will there be a recession? How will new tariffs impact the ...

Metsera , Inc. (NASDAQ:MTSR), a pharmaceutical company with a market capitalization of $1.95 billion, announced today the appointment of Jon P. Stonehouse to its Board of Directors and Matthew Lang as ...

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...